Kazunori Ochiai

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi et al. · The Lancet · 2009 · 731 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +9

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

Noriyuki Katsumata, Makoto Yasuda, Seiji Isonishi et al. · The Lancet Oncology · 2013 · 468 citations

Gastrointestinal Oncology, Conventional Paclitaxel, Medicine +9

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research · 2005 · 394 citations

Identification by cDNA microarray of genes involved in ovarian carcinogenesis.

Kenji Ono, Toshihiro Tanaka, Tatsuhiko Tsunoda et al. · PubMed · 2000 · 311 citations

Malignant Disease, Dna Microarray Consisting, Genetics +15

Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection

Toyomi Satoh, Masayuki Hatae, Yoh Watanabe et al. · Journal of Clinical Oncology · 2010 · 199 citations